CEO Dr Samantha South and Non-Executive Director Leanne Kite were pleased to represent Patrys at the 20th Bioshares Biotech Summit in Queenstown, New Zealand.

The conference provided an excellent opportunity to engage with investors and industry participants, while showcasing Patrys’ differentiated strategy to advance its lead delirium program through the FDA’s 505(b)(2) pathway.

Thank you to everyone who met with the team over the course of the event. We look forward to updating the market as we continue to deliver on our upcoming clinical milestones.